Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort

BACKGROUND: Amikacin and kanamycin are mainly used for treating multidrug-resistant tuberculosis (MDR-TB), especially in developing countries where the burden of MDR-TB is highest. Their protracted use in MDR-TB treatment is known to cause dose-dependent irreversible hearing loss, requiring hearing...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagwa, Evans L., Ruswa, Nunurai, Mavhunga, Farai, Rennie, Timothy, Leufkens, Hubert G. M., Mantel-Teeuwisse, Aukje K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675035/
https://www.ncbi.nlm.nih.gov/pubmed/26654443
http://dx.doi.org/10.1186/s40360-015-0036-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675035/
https://www.ncbi.nlm.nih.gov/pubmed/26654443
http://dx.doi.org/10.1186/s40360-015-0036-7

Ejemplares similares